Christos Sotiriou, MD, PhD Breast Cancer Translational Research Laboratory J.-C. Heuson
Institut Jules BordetUniversité Libre de Bruxelles (ULB)
Brussels, Belgium
Systemic treatment of TN early and advanced BC
ESO-ESMO E
EBR Mas
tercla
ss 20
19
1. Biology of Triple Negative Breast Cancer
2. How can biology help with treatment choice?
Outline
ESO-ESMO E
EBR Mas
tercla
ss 20
19
1. Biology of Triple Negative Breast Cancer
2. How can biology help with treatment choice?
Outline
ESO-ESMO E
EBR Mas
tercla
ss 20
19
1. TNBC – PAM50 classifier
Garrido-Castro AC, et al. Cancer Discov 2019
ESO-ESMO E
EBR Mas
tercla
ss 20
19
TNBC molecular subtypes
BL1: Basal-like 1
BL2: Basal-like 2
IM: Immunomodulatory
M: Mesenchymal
MSL: Mesenchymal Stem-like
LAR: Luminal Androgen receptor
Lehmann BD, et al. JCI 2011
ESO-ESMO E
EBR Mas
tercla
ss 20
19
TNBC molecular subtypes – multiomic analysis
Significant up-regulation displayed in black, down-regulation in white
Bareche Y, et al. Ann Oncol 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
The PIK3 signalling pathway is alteredin 75% of LAR subtype patients
Bareche Y, et al. Ann Oncol 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
TNBC subtypes – multiomic analysis
BLIS: basal-like and immune-suppressed
IM: Immunomodulatory
LAR: Luminal Androgen receptor
MES: Mesenchymal-like
Jiang YZ, et al. Cancer Cell 2019
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Belli C, et al. Breast 2019
• Germline BRCA1/2 mutations in 10-20% of TNBC pts
• Somatic BRCA1/2 mutations in 3-5% of TNBC pts
In Homologous Recombination Deficiency (HRD) the DNA repair mechanism engages non-homologous pathways, more prone to error and to genome instability
BRCA mutated tumours are sensitive to PARP inhibitorsand DNA damaging drugs, including platinum agents
2. BRCA and HRD
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Davies H, et al. Nature Med 2017
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
HRDetect as a probabilistic classifier. (A) Pie charts depicting the BRCA1 and BRCA2 mutation status of samples in the data set of 560 breast cancers. (B) The HRDetect scores of 560 breast cancer samples ordered from lowest to highest score across the x axis. Colored bars represent both samples with monoalleleic mutations and those with loss of the second allele.
• HRDetect identified BRCA1/BRCA2-deficient tumors with 98.7% sensitivity
• Additional tumors with functional BRCA1/BRCA2 deficiency where no mutation was detected were also identified
ESO-ESMO E
EBR Mas
tercla
ss 20
19
3. Immune microenvironment
Savas P, et al. Nat Rev Clin Oncol 2016
ESO-ESMO E
EBR Mas
tercla
ss 20
19
TNBC
HER2+
STAT1 metageneUntreated BC
Desmedt C et al. Clin Cancer Res, 2008
ESO-ESMO E
EBR Mas
tercla
ss 20
19
TNBC
HER2+
Ignatiadis M et al. J Clin Oncol, 2012
ESO-ESMO E
EBR Mas
tercla
ss 20
19
TNBC
Loi et al. J Clin Oncol, 2013
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Tumor Immune Micro-Environment – TIME subtypes
ID: Immune Desert
MR: Margin-Restricted
SR: Stroma-Restricted
FI: Fully Inflamed
Gruosso T, et al. J Clin Invest 2019
ESO-ESMO E
EBR Mas
tercla
ss 20
19
TNBC subtypes have different immune landscape
Bareche Y, et al. Manuscript submitted
Distribution of the TIME subtypes within each TNBC molecular subtype
Associations between 16 immune cell subsets scores with TNBC molecular subtypesESO-E
SMO EEBR M
aster
class
2019
Low immune infiltration in metastatic BC
Robinson D et al., Nature 2017
MImmScore(metastastic immune infiltration)
TILs (129 patients)
Savas P et al., Nat Med 2018ESO-ESMO E
EBR Mas
tercla
ss 20
19
“High” immune signal
1) More frequent in triple negative (TNBC) and HER2+ breast cancer (BC)
2) Improved outcome in TNBC and HER2+ BCs
3) Increased response to neoadjuvant chemotherapy
4) Low immune infiltration in metastatic BC
5) Immune ”signal” and response to checkpoint blockade?
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Garrido-Castro AC, et al. Cancer Discov 2019
Heterogeneity of TNBC
ESO-ESMO E
EBR Mas
tercla
ss 20
19
1. Biology of Triple Negative Breast Cancer
2. How can biology help with treatment choice?
Outline
ESO-ESMO E
EBR Mas
tercla
ss 20
19
1. Early disease
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Cortazar P, et al. Lancet 2014
pCR is an excellent surrogate for EFS and OS
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Association between pCR and long-term outcome in TNBC
Cortazar P, et al. Lancet 2014
ESO-ESMO E
EBR Mas
tercla
ss 20
19
(B) Univariable analysis of TILs as a continuous marker for prediction of pCR(C) Multivariable analysis of TILs as a continuous marker for prediction of pCR
Denkert C, et al. Lancet Oncol 2018
TILs and pCR: Pooled analysis of 3771 BC patients treated with neoadjuvant therapy
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Loi S, et al. JCO 2019
TILs and prognosis: Pooled analysis of 2148 early-stage TNBC patients treated with adjuvant chemotherapy
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Loi S, et al. JCO 2019
TILs and prognosis: Pooled analysis of 2148 early-stage TNBC patients treated with adjuvant chemotherapy
ESO-ESMO E
EBR Mas
tercla
ss 20
19
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Poggio F, et al. Ann Oncol 2018
Role of platinum-based neoadjuvant chemotherapy in TNBC
(A) Odds ratios for pCR of platinum-based versus platinum-free (Controls) neoadjuvant chemotherapy in the randomized controlled trials using anthracycline- and taxane-based chemotherapy in both treatment arms
• Meta-analysis of 9 RCTs
• Overall, platinum-based neoadjuvant CHT significantly increased pCR rate from 37.0%to 52.1% (OR 1.96)
• Two RCTs (GeparSixto and CALGB 40603) reported the survival outcomes: no significant differences in EFS nor in OS were observed
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Δ in pCR cannot be used as surrogate for HR for DFS or OS
Spring LM, et al. SABCS 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Predictive Model: the magnitude of pCR change is predictive of treatmenteffects on EFS with a certain amount of uncertainty
Spring LM, et al. SABCS 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Prediction: HR EFS vs ΔpCR (example)
• The CALGB 40603 trial resulted in pCR improvement of 13% (41% 54%) with the addition of carboplatin to standard chemotherapy, which would correspond to an EFS HR ≈ 0.87 (95% PI: 0.84-0.89), based on this prediction model.
Assuming 80% power and a 1:1 randomization ratio, 1,381 events must be observed to achieve statistical significance at 0.05 level (two-sided).
• In CALGB 40603 the HR for EFS for carboplatin was 0.84 (95% CI: 0.58-1.22), but this was not statistically significant (only 110 events were observed).
• Common theme for neoadjuvant studies, which are typically powered for primary endpoint of pCR and not secondary long-term survival outcomes.
Spring LM, et al. SABCS 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Poggio F, et al. Ann Oncol 2018
Role of platinum-based neoadjuvant chemotherapy in TNBC
Odds ratios for pCR of platinum-based vs platinum-free (Controls) neoadjuvant chemotherapy in: (A) BRCA-mutated breast cancer patients; (B) breast cancer patients without BRCA mutations
• Among the 96 BRCA-mutated patients included in 2 RCTs, the addition of carboplatin was not associated with significantly increased pCR rate (from 54.3% to 56.2%, OR 1.17)
BRCA-mutated TNBC may also have increasedvulnerability to anthracycline-induced single-stranded and double-stranded DNA breaks
ESO-ESMO E
EBR Mas
tercla
ss 20
19
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Blum JL, et al. JCO 2017
• Three adjuvant trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49)• Patients randomized to TC for six cycles (2125 pts) or to a standard TaxAC regimen (2117 pts)• TaxAC regimens improved iDFS in patients with high-risk HER2-negative BC
Adjuvant chemotherapy – role of anthracycline
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, reduces the 10-year risk of recurrence
☞
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*, Lancet 2019
ESO-ESMO E
EBR Mas
tercla
ss 20
19
ESO-ESMO E
EBR Mas
tercla
ss 20
19
What can we do for patients with residual disease?
Does more treatmentimprove outcome?
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Masuda N, et al. NEJM 2017
• Overall, DFS and OS were longer in the capecitabine group than in the control group (74.1% vs 67.6% and 89.2% vs83.6% at 5 years, respectively)
• TNBC subgroup: - 5-year DFS rate 69.8% vs 56.1%- 5-year OS rate 78.8% vs 70.3%
Residual disease after NACT in TNBC – CREATE-X trial
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing
Kim C, et al. Cell 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
• Genotypic evolution during chemotherapy was measured using single cell DNA copy number profiling (Navin et al. 2011, Nature) of N=900 cells
• Phenotypic evolution during chemotherapy was measured using nanowell single cell RNA sequencing (Gao et al. 2016, Nature Comm.) of N=6862 cells
4 clonal extinction 4 clonal persistence
• Single cell copy number profiling
• single cell RNA sequencing
• Single cell copy number profiling
• single cell RNA sequencing
Kim C, et al. Cell 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
• Three tumor clones were identified (A,B) that shared common CNAs in MYC, MET, APC and TP53, and divergent CNAs in ABL2, PTEN, FOXO3 and RELN
• 111 single tumor cells were profiled from 2 matched time points (pre/post treatment)
• All three clones were not detected in the post-treatment time point sample
Single Cell CNA Profiling in a Clonal Extinction Patients
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Adaptive Evolution in Clonal Persistence Patients
• Single cell copy number profiling of 98 cells from Patient 14 identified 3 major aneuploid subpopulations
• Clone A emerged in response to NAC, but was pre-existing at a low frequency (7.7%) in the pre-treatment sample and expanded to 71.8% in the post-treatment tissue
• Chemoresistant clone A had two focal hemizygous deletions on chrom 3p, including IL5RA and RARB ESO-E
SMO EEBR M
aster
class
2019
Take home messages - TNBC, early setting (neo)adjuvant therapy
1) Anthracyclines/taxanes-base chemotherapy remains the standard of care (dose dense schedule)
2) To favor neoadjuvant >>> adjuvant
3) Capecitabine should be considered in TNBC with residual disease
4) PARP inh still under investigation (i.e. Olympia)
5) TILs important prognostic factor ( clinical utility remains uncertain, immunotherapy?)ESO-E
SMO EEBR M
aster
class
2019
2. Metastatic disease
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Role of immunotherapy – IMpassion130
Schmid P, et al. NEJM 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
IMpassion130 – results – PFS
Schmid P, et al. NEJM 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
IMpassion130 – results – OS (interim analysis)
Schmid P, et al. NEJM 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
IMpassion130 – pts characteristics
Schmid P, et al. NEJM 2018
ESO-ESMO E
EBR Mas
tercla
ss 20
19
IMpassion130 – Analyses of PFS in key subgroups
Schmid P, et al. NEJM 2018
☞
☞
☞ESO-ESMO E
EBR Mas
tercla
ss 20
19
Tutt A, et al. Nature Med 2018
Response rates documented in the overall population, BRCA1/2 mutated and BRCAness subgroups
BRCA1/2 mutated TNBC – role of carboplatin – TNT Trial
ESO-ESMO E
EBR Mas
tercla
ss 20
19
BRCA1/2-mutated TNBC – role of PARPi – OlympiAD trial
Robson M, et al. NEJM 2017
mPFS 7.0 vs 4.2 months
☞☞
ESO-ESMO E
EBR Mas
tercla
ss 20
19
BRCA1/2-mutated TNBC – role of PARPi – EMBRACA trial
Litton JK, et al. NEJM 2018
☞☞
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Sacituzumab Govitecan-hziy in ≥ 3rd line
Bardia A, et al. NEJM 2019
• Sacituzumab govitecan-hziy is an antibody–drug conjugate in which SN-38 (an active metabolite of irinotecan), is coupled to the humanized antitrophoblast cell-surface antigen 2 (Trop-2) monoclonal antibody hRS7 IgG1κ
• Trop-2, a transmembrane calcium signal transducer, is expressed in almost 90% of TNBC
ESO-ESMO E
EBR Mas
tercla
ss 20
19
PD-L1+ (and de novo oligometastatic BC,
high TILs) ?
Atezolizumab+
nab-paclitaxel
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Heterogeneity of TNBC – opportunities for personalized treatment
Bareche Y, et al. Manuscript submitted
ESO-ESMO E
EBR Mas
tercla
ss 20
19
Acknowledgments
Mattia Rediti
ESO-ESMO E
EBR Mas
tercla
ss 20
19